Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$3.01 USD
+0.06 (1.86%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $3.03 +0.03 (0.83%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MTNB 3.01 +0.06(1.86%)
Will MTNB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MTNB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MTNB
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
MTNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Other News for MTNB
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed: Matinas BioPharma’s Solid Financials and Promising Drug Development
Matinas BioPharma Holdings Inc (MTNB) Q2 2024 Earnings Call Transcript Highlights: Financial ...
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update